GW Pharmaceuticals PLC- (NASDAQ:GWPH) has been assigned an average rating of “Buy” from the twelve ratings firms that are covering the firm. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $149.61.
GWPH has been the subject of a number of research reports. Goldman Sachs Group Inc initiated coverage on shares of GW Pharmaceuticals PLC- in a research report on Friday, January 13th. They set a “buy” rating and a $189.00 target price for the company. TheStreet upgraded shares of GW Pharmaceuticals PLC- from a “d+” rating to a “c-” rating in a research report on Tuesday, March 14th. Piper Jaffray Companies set a $147.00 target price on shares of GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a research report on Tuesday, February 7th. Cantor Fitzgerald set a $208.00 target price on shares of GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a research report on Tuesday, February 7th. Finally, Cowen and Company set a $135.00 target price on shares of GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a research report on Monday, February 6th.
Several institutional investors have recently bought and sold shares of GWPH. Capital Research Global Investors raised its position in GW Pharmaceuticals PLC- by 14.9% in the third quarter. Capital Research Global Investors now owns 3,017,604 shares of the biopharmaceutical company’s stock worth $400,527,000 after buying an additional 390,930 shares in the last quarter. Prudential PLC raised its position in GW Pharmaceuticals PLC- by 75.8% in the fourth quarter. Prudential PLC now owns 2,050,212 shares of the biopharmaceutical company’s stock worth $229,111,000 after buying an additional 884,106 shares in the last quarter. Scopia Capital Management LP purchased a new position in GW Pharmaceuticals PLC- during the third quarter worth $250,218,000. Capital World Investors raised its position in GW Pharmaceuticals PLC- by 74.1% in the third quarter. Capital World Investors now owns 760,800 shares of the biopharmaceutical company’s stock worth $100,981,000 after buying an additional 323,700 shares in the last quarter. Finally, Redmile Group LLC purchased a new position in GW Pharmaceuticals PLC- during the third quarter worth $72,460,000. 72.30% of the stock is owned by institutional investors and hedge funds.
Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) traded down 0.0612% on Monday, hitting $116.1189. 156,392 shares of the company’s stock were exchanged. GW Pharmaceuticals PLC- has a 12-month low of $74.05 and a 12-month high of $137.88. The company’s 50-day moving average price is $121.66 and its 200 day moving average price is $121.13. The stock’s market cap is $2.93 billion.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its earnings results on Tuesday, February 7th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.58. The company earned $2.54 million during the quarter, compared to analysts’ expectations of $1.85 million. GW Pharmaceuticals PLC- had a negative net margin of 702.90% and a negative return on equity of 20.07%. The firm’s quarterly revenue was down 32.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.06) earnings per share. On average, equities analysts predict that GW Pharmaceuticals PLC- will post ($5.06) earnings per share for the current fiscal year.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2065150/gw-pharmaceuticals-plc-gwph-receives-149-61-consensus-target-price-from-analysts.html
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.